yahoo_financeOriginal article
ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Zynlonta Outlook
Data ReadoutnegativeZynlontaNegative
AI Analysis
Summary
ADC Therapeutics' fair value fell following negative LOTIS 5 trial results for Zynlonta, reshaping the commercial outlook for the drug.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
LOTIS 5 trial results reshaped Zynlonta outlook negatively, causing fair value to fall
Importance:7/10
Sentiment:
-0.70
clinical_trialdata_readoutvaluation_impactZynlontaLOTIS_5
Related Companies
Read the original article
Published by yahoo_finance on August 16, 2026 3:15 AM